跳至主要内容
临床试验/PER-097-09
PER-097-09已完成未知

Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in Patients With Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation

CureTech Ltd,0 个研究点目标入组 0 人开始时间: 2010年2月18日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
CureTech Ltd,

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 90(—)

入选标准

  • Patient´s age is 18 years or older, both genders.
  • Confirmed Diffuse Large B-cell Lymphoma, transformed follicular lymphoma, diffuse mixed cell lymphoma or primary mediastinal large cell lymphoma with B-cell lineage.
  • The lymphoma is chemosensitive.
  • The lymphoma did not progress since pre-transplant chemotherapy.
  • ECOG performance status 0-1.

排除标准

  • Serious other illness.
  • Active autoimmune disease.
  • Type 1 diabetes.
  • Known immune deficiency.
  • Clinical evidence of primary or secondary brain or spinal cord involvement by lymphoma.
  • Active bacterial, fungal, or viral infection.
  • Positive HIV, Hepatitis B surface antigen plus viremia, or Hepatitis C antibody plus viremia.
  • Pregnant or nursing (positive pregnancy test).
  • Other concurrent clinical study or investigational therapy.

研究者

发起方
CureTech Ltd,

相似试验